Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
Authors
Keywords
Metastasis, Steroids, Immunotherapy, Cancer immunotherapy, Albumins, Multivariate analysis, Immune response, Machine learning
Journal
PLoS One
Volume 16, Issue 6, Pages e0252537
Publisher
Public Library of Science (PLoS)
Online
2021-06-02
DOI
10.1371/journal.pone.0252537
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers
- (2019) Maria Panagopoulou et al. ONCOGENE
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Neutrophil–lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)
- (2019) Fangping Ren et al. OncoTargets and Therapy
- Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer
- (2019) Nadina Tinsley et al. ONCOLOGIST
- Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
- (2019) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
- (2019) Wungki Park et al. BRITISH JOURNAL OF CANCER
- Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
- (2019) Lorenza Landi et al. Journal for ImmunoTherapy of Cancer
- EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
- (2019) Arsela Prelaj et al. Cancers
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
- (2018) Mina Georgieva et al. LUNG CANCER
- Recovery of gut microbiota of healthy adults following antibiotic exposure
- (2018) Albert Palleja et al. Nature Microbiology
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- MatureP: prediction of secreted proteins with exclusive information from their mature regions
- (2017) Georgia Orfanoudaki et al. Scientific Reports
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Proton pump inhibitors affect the gut microbiome
- (2015) Floris Imhann et al. GUT
- Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss
- (2015) Lisa Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort
- (2015) Haifeng Sun et al. PLoS One
- Role of the Microbiota in Immunity and Inflammation
- (2014) Yasmine Belkaid et al. CELL
- Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System
- (2013) B. J. Laird et al. CLINICAL CANCER RESEARCH
- Definition and classification of cancer cachexia: an international consensus
- (2011) Kenneth Fearon et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now